Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-12-30
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALDWALD — Waldencast PLC
NASDAQ · Consumer Products · Consumer Products
$0.85-55.18%Market cap202.65M
- Latest Close
- $0.85
- 30-Day Move
- -55.2%
- Market Cap
- $203M
- Shares Outstanding
- 128,260,000
- P/B Ratio
- 0.75
- ROE
- -6.4%
Analyst consensus: Buy · 11 analysts
NASDAQ:WALDConsumer Products / Consumer ProductsDelayed public snapshot
Waldencast PLC
A read-only Alphactor snapshot forWaldencast PLC. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$0.85
30-Day Move
-55.2%
Market Cap
$203M
Shares Outstanding
128,260,000
P/B Ratio
0.75
ROE
-6.4%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$0.85
-55.2%last 90 delayed daily bars
Market cap$203M
90D High
$2.03
90D Low
$0.77
Avg Volume
118,960
What stands out
Gross margin is running at 70.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -52.2%, useful for comparing WALD against peers in Consumer Products.
WALD is down 55.2% over the last 30 trading days shown on this page.
Latest operating income is $-65M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$9.68
Rule of 40
-6.7%
Fundamentals snapshot
Latest Close
$0.85
30-Day Move
-55.2%
Market Cap
$203M
Shares Outstanding
128,260,000
P/B Ratio
0.75
ROE
-6.4%
ROA
-4.3%
Gross Margin
70.0%
Operating Margin
-60.1%
Net Margin
-52.2%
Debt / Equity
0.25
Current Ratio
1.35
Latest Revenue
$272M
Financial statement snapshot
Revenue
$272M
Gross Profit
$183M
Operating Income
$-65M
Net Income
$-230M
Gross Margin
6998.0%
Net Margin
-5217.0%
Current Ratio
1.35
Debt / Equity
0.25
Valuation snapshot
Fair Value
$9.68
Upside / Downside
+1036.8%
Signal
Undervalued
Implied Growth
--
EV/Rev
$9.68
Growth Assumption
24.1%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$0.85
Composite Fair Value
$9.68
EV/Rev
$9.68
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
-0.32
Distress
Piotroski
3
Weak (0-3)
Cash Conversion
0.06x
Rule of 40
-6.7%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2021-12-31 | $142M | $-2M | $-20M | $2M |
| 2023-12-31 | $218M | $-82M | $-90M | $-32M |
| 2024-12-31 | $274M | $-54M | $-42M | $-12M |
| 2025-12-31 | $272M | $-65M | $-230M | $-16M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-11-16
Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual MeetingPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-10-08
Obagi Medical Launches Nu-Cil® BioStim™ Scalp SerumPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-08-18
Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive TransformationPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2025-07-23
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical BrandAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 910,779 | 0.01% | 2026-02-28 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 438,160 | 0.00% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Value ETF | 354,283 | 0.00% | 2026-02-28 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 206,692 | 0.00% | 2025-11-30 |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 106,148 | 0.00% | 2026-01-31 |
| Quantitative Master Series LLC-Master Small Cap Index Series | 73,371 | 0.00% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 66,548 | 0.00% | 2026-02-28 |
| TIAA-CREF Funds-Nuveen Small Cap Blend Index Fund | 55,467 | 0.00% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$10M
--
Geode Capital Management
Filed 2025-08-08
$1M
+62.2%
Vanguard Group
Filed 2025-08-11
$646,286
+82.9%
Northern Trust
Filed 2025-08-13
$595,931
+60.1%
Analyst consensus?
Rating(?)
3.82
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
11
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.